For the year ending 2025-12-31, CATX made $884K in revenue. -$103,121K in net income. Net profit margin of -11665.27%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Grant revenue | 884 | 1,454 | ||
| Research and development | 84,215 | 41,638 | ||
| General and administrative | 30,233 | 26,613 | ||
| Goodwill impairment | 0 | 24,062 | ||
| Loss on disposal of property and equipment | 0 | -27 | ||
| Total operating expenses | 114,448 | 92,340 | ||
| Operating loss | -113,564 | -90,886 | ||
| Interest income | 8,114 | 10,515 | ||
| Interest and other expense | 376 | - | ||
| Other income from a related party (note 3) | 1,400 | - | ||
| Equity in loss of affiliate | -2 | -8 | ||
| Interest and other expense, net | - | 48 | ||
| Total non-operating income, net | 9,136 | 10,459 | ||
| Net loss from continuing operations | -104,428 | -80,427 | ||
| Net gain (loss) from discontinued operations | 514 | -949 | ||
| Net loss before deferred income tax benefit | -103,914 | -81,376 | ||
| Deferred income tax benefit | -793 | -2,097 | ||
| Net loss | -103,121 | -79,279 | ||
| Basic EPS | -1.4 | -1.23 | ||
| Diluted EPS | -1.4 | -1.23 | ||
| Basic Average Shares | 73,813,000 | 64,425,000 | ||
| Diluted Average Shares | 73,813,000 | 64,425,000 | ||
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)